Statement Of Cash Flows [Abstract]

BerGenBio - Filing #2542730

Concept 2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
As at
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
As at
2021-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Profit (loss)
0 NOK
0 NOK
190,401,000 NOK
190,401,000 NOK
0 NOK
0 NOK
302,122,000 NOK
302,122,000 NOK
0 NOK
0 NOK
Adjustments to reconcile profit (loss) [abstract]
Adjustments for provisions
42,000 NOK
969,000 NOK
Adjustments for unrealised foreign exchange losses (gains)
1,613,000 NOK
3,280,000 NOK
Adjustments for share-based payments
3,135,000 NOK
3,466,000 NOK
Cash flows from (used in) operating activities
225,101,000 NOK
288,231,000 NOK
Cash flows from (used in) investing activities [abstract]
Proceeds from sales of property, plant and equipment, classified as investing activities
0 NOK
299,000 NOK
Interest received, classified as investing activities
3,055,000 NOK
2,949,000 NOK
Cash flows from (used in) investing activities
3,055,000 NOK
3,248,000 NOK
Cash flows from (used in) financing activities [abstract]
Proceeds from issuing shares
262,048,000 NOK
3,218,000 NOK
Payments of lease liabilities, classified as financing activities
193,000 NOK
307,000 NOK
Cash flows from (used in) financing activities
224,884,000 NOK
2,904,000 NOK
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes
2,838,000 NOK
282,080,000 NOK
Effect of exchange rate changes on cash and cash equivalents [abstract]
Effect of exchange rate changes on cash and cash equivalents
2,780,000 NOK
3,764,000 NOK
Cash and cash equivalents
156,421,000 NOK
150,803,000 NOK
436,646,000 NOK

Talk to a Data Expert

Have a question? We'll get back to you promptly.